These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22843554)

  • 21. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.
    Peng J; Yang LX; Zhao XY; Gao ZQ; Yang J; Wu WT; Wang HJ; Wang JC; Qian J; Chen HY; Jin L; Bai CX; Han BH; Wang WM; Lu DR
    Tumour Biol; 2013 Apr; 34(2):953-61. PubMed ID: 23412975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy.
    Zheng Y; Deng Z; Tang M; Cai P
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):495-502. PubMed ID: 33461346
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
    Kim SH; Kim MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY; Ling H; Lee GW
    Am J Clin Oncol; 2015 Jun; 38(3):294-9. PubMed ID: 23689644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
    Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
    Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
    J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
    Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
    Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
    Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
    Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
    Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
    Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
    Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
    Cao S; Wang S; Ma H; Tang S; Sun C; Dai J; Wang C; Shu Y; Xu L; Yin R; Song X; Chen H; Han B; Li Q; Wu J; Bai C; Chen J; Jin G; Hu Z; Lu D; Shen H
    Pharmacogenomics J; 2016 Feb; 16(1):41-6. PubMed ID: 25823687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
    Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population.
    Xu J; Yin Z; Shen H; Gao W; Qian Y; Pei D; Liu L; Shu Y
    PLoS One; 2013; 8(11):e79135. PubMed ID: 24223174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.